PUBLISHER: GlobalData | PRODUCT CODE: 1395968
PUBLISHER: GlobalData | PRODUCT CODE: 1395968
Structural Heart Occlusion Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
The model discusses in detail the impact of COVID-19 on Structural Heart Occlusion Devices market for the year 2020 and beyond. Congenital Heart Disease (CHD) is structural heart defects ranging in severity that are present at birth. Atrial septal defect (ASD) and ventricular septal defect (VSD) are the two structural abnormalities. Atrial septal defect, or ASD, is caused by a deficiency in the atrial septum leading to a failure of overlap resulting in a hole in the atrial septum. Ventricular septal defect, or VSD, occurs during pregnancy due to deficiencies in the septum that separates the left and right ventricles leading to a hole in the septum. Occluder devices are recommended for the treatment of atrial septal defects (ASD) and ventricular septal defects (VSD). This device releases a self-expandable nitinol mesh that prevents blood flow through the atrial hole. Over time, heart tissue develops over the nitinol mesh to fully occlude the defect.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Structural Heart Occlusion Devices market and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Boston Scientific Corp, Abbott Laboratories, AtriCure Inc, Lifetech Scientific Corporation, Occlutech GmbH, pfm medical ag, W. L. Gore & Associates Inc, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable